

| | | | | |
|---|------------------------|---------------|------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10582304 | |
| | Filing Date | | 2007-04-20 | |
| | First Named Inventor | Kimura et al. | | |
| | Art Unit | 1643 | | |
| | Examiner Name | Anne Gussow | | |
| | Attorney Docket Number | 14875-0166US1 | | |

| U.S.PATENTS | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 7115373 | B2 | 2009-10-27 | HASHIDA et al. | |

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

| U.S.PATENT APPLICATION PUBLICATIONS | | | | | | Remove |
|-------------------------------------|---------|--------------------|------------------------|------------------|---|--|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 20090297501 | A1 | 2009-12-03 | IGAWA et al. | |
| | 2 | 20030103979 | A1 | 2003-06-05 | LEUNG et al. | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

| FOREIGN PATENT DOCUMENTS | | | | | | | | Remove |
|--------------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|--------------------------|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | 1 | WO97034632 | WO | | 1997-09-25 | LEUNG et al. | | <input type="checkbox"/> |
| | 2 | WO03002607 | WO | A1 | 2003-01-09 | LEUNG et al. | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10582304 |
| Filing Date | 2007-04-20 |
| First Named Inventor | Kimura et al. |
| Art Unit | 1643 |
| Examiner Name | Anne Gussow |
| Attorney Docket Number | 14875-0166US1 |

| | | | | | | | |
|---|--------------|----|--|------------|-----------------|--|--------------------------|
| 3 | JP10508868 | JP | | 1998-09-02 | UCKUN et al. | | <input type="checkbox"/> |
| 4 | JP2005529616 | JP | | 2005-10-06 | DEVERAUX et al. | | <input type="checkbox"/> |
| 5 | WO02028894 | WO | | 2002-04-11 | KOMATANI et al. | | <input type="checkbox"/> |
| 6 | WO2005004912 | WO | | 2005-01-20 | NAKAMURA et al. | | <input type="checkbox"/> |
| 7 | WO2008007755 | WO | | 2008-01-17 | KIMURA et al. | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|---|--------------------------|
| | 1 | SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," Current Opinion in Hematology, 12:444-450 (2005) | <input type="checkbox"/> |
| | 2 | U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages | <input type="checkbox"/> |
| | 3 | U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed October 27, 2009, 4 pages | <input type="checkbox"/> |
| | 4 | FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|------------|
| Application Number | | 10582304 |
| Filing Date | | 2007-04-20 |
| First Named Inventor | Kimura et al. | |
| Art Unit | 1643 | |
| Examiner Name | Anne Gussow | |
| Attorney Docket Number | 14875-0166US1 | |

| | | |
|----|---|--------------------------|
| 5 | BORDEN et al., "Lymphokines and Cytokines as Cancer Treatment," Cancer, 65:800-814 (1990) | <input type="checkbox"/> |
| 6 | BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," CA Cancer J. Clin., 49:353-361 (1999) | <input type="checkbox"/> |
| 7 | GRANZIERO et al., "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," Eur. J. Immunol., 29:1127-1138 (1999) | <input type="checkbox"/> |
| 8 | U.S. EXAMINER ELLY GERALD STOICA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages | <input type="checkbox"/> |
| 9 | U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/548,727, mailed November 25, 2009, 29 pages | <input type="checkbox"/> |
| 10 | FISH & RICHARDSON, Amendment in Reply to Action dated June 8, 2009 in U.S. App. Ser. No. 10/530,696, filed November 30, 2009, 10 pages | <input type="checkbox"/> |
| 11 | FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 1, 2009 in U.S. App. Ser. No. 11/547,747, filed November 30, 2009, 12 pages | <input type="checkbox"/> |
| 12 | U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 2, 2009, 4 pages | <input type="checkbox"/> |
| 13 | U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed December 8, 2009, 33 pages | <input type="checkbox"/> |
| 14 | FISK et al., "Increased sensitivity of Adriamycin-selected Tumor Lines to CTL-mediated Lysis Results in Enhanced Drug Sensitivity," Cancer Res., 58:4790-4793 (1998) | <input type="checkbox"/> |
| 15 | JALILI et al., "Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells," Blood (ASH Annual Meeting Abstracts), 118 (11):701a-702a (#2376) (2007) | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10582304 |
| Filing Date | 2007-04-20 |
| First Named Inventor | Kimura et al. |
| Art Unit | 1643 |
| Examiner Name | Anne Gussow |
| Attorney Docket Number | 14875-0166US1 |

| | | |
|----|--|-------------------------------------|
| 16 | MELGUIZO et al., "Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells," Neoplasma, 50(2):91-96 (2003) | <input type="checkbox"/> |
| 17 | OZAKI et al., "Induction of myeloma cell death by a recombinant HLA class I-specific single-chain Fv diabody," Dai 65 Nihon Ketsueki Gakkai, Dai 45 kai Nihon Ketsueki Gakkai Sokai, Osaka (August 28-31, 2003) | <input checked="" type="checkbox"/> |
| 18 | OZAKI et al., "A recombinant HLA class I-specific single chain Fv diabody induces cell death in human lymphoid malignancies," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003) | <input type="checkbox"/> |
| 19 | PRADOS et al., "Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase," Neoplasma, 53(3):226-231 (2006) | <input type="checkbox"/> |
| 20 | SEKIMOTO et al., "Eradication of human myeloma cells by a recombinant HLA class I-specific single chain Fv diabody," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003) | <input type="checkbox"/> |
| 21 | SONNEVELD, "Multidrug resistance in haematological malignancies," J. Intern. Med., 247:521-534 (2000) | <input type="checkbox"/> |
| 22 | TSUKAKOSHI, New Pharmacology, 3rd revised edition, Nankodo Co., Ltd., 557-568 (1997) | <input type="checkbox"/> |
| 23 | JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2008/054443, dated May 27, 2008, 7 pages | <input type="checkbox"/> |
| 24 | U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed January 7, 2010, 46 pages | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10582304 |
| Filing Date | 2007-04-20 |
| First Named Inventor | Kimura et al. |
| Art Unit | 1643 |
| Examiner Name | Anne Gussow |
| Attorney Docket Number | 14875-0166US1 |

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.